Effect of Tetrabenazine on Stroop Interference in HD
NCT01834911, Phase 4, Completed, New York Medical College; results first posted 2025-05-28
Trial 12
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Effect of Tetrabenazine on Stroop Interference in HD | ClinicalTrials.gov |
| NCT number | NCT01834911 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Phase 4 | ClinicalTrials.gov |
| Enrollment | 2 participants, actual | ClinicalTrials.gov |
| Lead sponsor | New York Medical College | ClinicalTrials.gov |
| Conditions | Huntington Disease | ClinicalTrials.gov |
| Interventions | Tetrabenazine withdrawal | ClinicalTrials.gov |
| First posted | 2013-04-18 | ClinicalTrials.gov |
| Last updated | 2025-05-28 | ClinicalTrials.gov |
| Results first posted | 2025-05-28 | ClinicalTrials.gov |
| Limitations and caveats | Statistical analysis could not be performed as only one subject was able to provide complete study data. | ClinicalTrials.gov |
Registered outcomes 1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in Stroop Interference Score | 72 hours | Participants will have Stroop Visual Interference Scores measured while OFF tetrabenazine for at least 3 days. Two doses of 12.5 mg tetrabenazine will be subsequently administered: first dose just after the Stroop test and second dose 3 hours later. Stroop Visual Interference Scores will be measured again in the ON state, 6 hours after the initial OFF measurement. Patients are analyzed according to Stroop test using Golden's Interference score (theoretical min -50, theoretical max about 98) calculated from \[(W × C)/(W + C)\] - CW, where C=color score (0-100), W=word score (0-100), CW=color word score (0-100). The Interference score analyzes cognitive interference during trials of reading of a list of color words which are printed in a different color. Lower or more negative scores are clinically better as they indicate less interference. | ClinicalTrials.gov |
Outcomes 1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|---|---|---|---|---|---|
| PRIMARY | Change in Stroop Interference Score | 72 hours | Only 1 patient could complete all conditions of the Stroop test. The delta between on and off Stroop test was 1 using Golden's score \[(W × C)/(W + C)\] - CW | score on a scale | NUMBER | ClinicalTrials.gov |
Results by group 2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|---|---|---|---|---|---|
| Change in Stroop Interference Score | Tetrabenazine Withdrawal | Interference score OFF | -1.97 | score on a scale | ClinicalTrials.gov | |
| Change in Stroop Interference Score | Tetrabenazine Withdrawal | Interference score ON | -1 | score on a scale | ClinicalTrials.gov |
Participant flow 3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|---|---|---|---|---|
| Overall Study | STARTED | Tetrabenazine Withdrawal | 2 | ClinicalTrials.gov | |
| Overall Study | COMPLETED | Tetrabenazine Withdrawal | 2 | ClinicalTrials.gov | |
| Overall Study | NOT COMPLETED | Tetrabenazine Withdrawal | 0 | ClinicalTrials.gov |
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 3
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|---|---|---|---|
| Total, all-cause mortality | Tetrabenazine Withdrawal | 0 | 2 | ClinicalTrials.gov |
| Total, other adverse events | Tetrabenazine Withdrawal | 0 | 2 | ClinicalTrials.gov |
| Total, serious adverse events | Tetrabenazine Withdrawal | 0 | 2 | ClinicalTrials.gov |
Papers 1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|---|---|
| 22621818 | BACKGROUND | PubMed |
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)